Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 19;27(2):310-317.
doi: 10.5603/RPOR.a2022.0020. eCollection 2022.

Integrating stereotactic radiotherapy and systemic therapies

Isabella Palumbo  1 , Francesco Pasqualetti  2 , Durim Delishaj  2 , Alessandra Gonnelli  2 , Cynthia Aristei  1 , Simona Borghesi  3 , Luigi Pirtoli  4 , Liliana Belgioia  5 , Stefano Arcangeli  6
Affiliations
Review

Integrating stereotactic radiotherapy and systemic therapies

Isabella Palumbo et al. Rep Pract Oncol Radiother. .

Abstract

This paper focuses on stereotactic radiotherapy (SRT ) interactions with targeted therapies and immune system modulating agents because SRT inevitably interacts with them in the treatment of oligometastatic patients. Radiation oncologists need to be aware of the advantages and risks of these interactions which can, on one hand, enhance the effect of therapy or, on the other, potentiate reciprocal toxicities. To date, few prospective studies have evaluated the interactions of SRT with new-generation drugs and data are mainly based on retrospective experiences, which are often related to small sample sizes.

Keywords: immune system modulating drugs; immunotherapy; oligometastasis; radiosurgery; stereotactic radiotherapy; targeted therapies.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest The authors have no conflict of interest to declare.

References

    1. Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013;14(1):e28–e37. doi: 10.1016/S1470-2045(12)70510-7. - DOI - PubMed
    1. Zeng J, Baik C, Bhatia S, et al. Combination of stereotactic ablative body radiation with targeted therapies. Lancet Oncol. 2014;15(10):e426–e434. doi: 10.1016/S1470-2045(14)70026-9. - DOI - PubMed
    1. Arcangeli S, Jereczek-Fossa BA, Alongi F, et al. Combination of novel systemic agents and radiotherapy for solid tumors - part I: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy. Crit Rev Oncol Hematol. 2019;134:87–103. doi: 10.1016/j.critrevonc.2018.11.005. - DOI - PubMed
    1. Arcangeli S, Jereczek-Fossa BA, Alongi F, et al. Combination of novel systemic agents and radiotherapy for solid tumors - Part II: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment toxicity. Crit Rev Oncol Hematol. 2019;134:104–119. doi: 10.1016/j.critrevonc.2018.11.006. - DOI - PubMed
    1. Brown JM, Carlson DJ, Brenner DJ. The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? Int J Radiat Oncol Biol Phys. 2014;88(2):254–262. doi: 10.1016/j.ijrobp.2013.07.022. - DOI - PMC - PubMed

LinkOut - more resources